

Patent Application Attorney Docket No.PC30520A

I hereby certify that the Experimental in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 10th day of May, 2005.

Ву	Deather Randhah
	(Signature of person mailing) Heather Randhahn
	(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Anders Berkenstam et al. :

APPLICATION NO.: 09/143,828 : Examiner: Michael D. Pak

FILING DATE: 08/31/1998 : Group Art Unit: 1646

TITLE: NR112 RECEPTOR RELATED

POLYPEPTIDES, NUCLEIC ACID

SEQUENCES ENCODING THE SAME AND

USES THEREOF (As Amended)

Hon. Commissioner for Patents Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application Attorney Docket No.PC30520A

A prompt and favorable response is earnestly solicited.

Date: May 10, 2005

Nicholas I. Sepchuk, Jr. Attorney for Applicant(s)

Respectfully submitted,

Reg. No. 32,174

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(617) 551-3223

INFORMATION DISCLOSURE CITATION ATTY, DOCKET NO. PC30520										20.4	SED	IAL NO	00/14	2 020		
(Use several sheets it necessary) APPLICANT Anders Berkenstam et al.																
FILING DATE 08/31/1998 GROUP 1646 MAY 1 2 2005																
U.S. TATENT DOGGNERTO																
EXAMINER INITIAL		V	1/2	-340	Docu	JMENT NUN	MBER			DATE	NAME		CLASS	SUBCLASS	IF APPR	DATE OPRIATE
	ļ		6 TRA	EMAN:	9	1	8	4	7 B1	05/21/02	Evans et al		514	2		
	<u> </u>		6	8	0	9	1	7	8 B2	10/26/04	Evans et al		530	350		
-	1											İ				
	 	1														
	+	+									·					
	<u> </u>	_									·					
	ــــــــــــــــــــــــــــــــــــــ	_1_	i				FORE	GN PAT	ENT DO	CUMENT	rs	1				
					-							I				
				DOC	CUMENT NUI	MBER				DATE	COUNTRY CLASS SUBCLASS TRANS			LATION		
	т —	_													YES	NO
	<u> </u>															
`																
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
T	T															
	+		Blumb	Blumberg, Bruce et al., "SXR, a novel steroid and xenobiotic-sensing nuclear receptor", Genes & Development, 12:3195-3205, 1998.												
			Fukuen, Shuichi, et al., "Identification of the novel splicing variants for the hPXR in human livers", Biochemical and Biophysical Research Communications 298 (2002), 433-438.													
			Kliewer, Steven A., et al., "An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway", Cell,													
	+		Vol. 92, 73-82, January 9, 1998.													
			Lehmann, Jürgen M. et al., "The Human Orphan Nuclear Receptor PXR is Activated by Compounds That Regulate CYP3A4 Gene Expression and Cause Drug Interactions", <i>J. Clin Invest.</i> , The American Society for Clinical Investigation, Inc., Volume 102, Number 5, September 1998, 1016-1023.													
	Nuclear Receptors Nomenclature Committee, "A Unified Nomenclature System for the Nuclear Receptor Superfamily", Cell, Vol 97, 161-163, April 16, 1999.															
EXAMINER DATE CONSIDERED																
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE